| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $0 ) |
| | 2026 | 2025 | EXPRESSION THERAPEUTICS, INC. | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R43CA291373 | Allogeneic cell and gene therapy for neuroendocrine tumors | 000 | 1 | NIH | 4/6/2026 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $388,188 ) |
| | 2025 | 2025 | EXPRESSION THERAPEUTICS, INC. | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R43CA291373 | Allogeneic cell and gene therapy for neuroendocrine tumors | 000 | 1 | NIH | 12/4/2024 | $400,000 |
| | 2025 | 2023 | EXPRESSION THERAPEUTICS, INC. | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R43CA281633 | ADEPT-STAR therapy for high risk neuroblastoma | 000 | 1 | NIH | 1/30/2025 | -$11,812 |
|
| Issue Date FY: 2023 ( Subtotal = $400,000 ) |
| | 2023 | 2023 | EXPRESSION THERAPEUTICS, LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R43CA281633 | ADEPT-STAR therapy for high risk neuroblastoma | 000 | 1 | NIH | 9/19/2023 | $400,000 |
| | 2023 | 2019 | EXPRESSION THERAPEUTICS, LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R44HL110448 | Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic | 000 | 3 | NIH | 9/7/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2019 | EXPRESSION THERAPEUTICS LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R43HL146045 | A Microscale Platform for Augmentation of Cell Transduction (MPACT) to Enhance Ex Vivo Gene Transfer | 000 | 1 | NIH | 4/26/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | EXPRESSION THERAPEUTICS LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R44HL110448 | Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic | 000 | 3 | NIH | 7/30/2021 | $0 |
| | 2021 | 2019 | EXPRESSION THERAPEUTICS LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R43HL146045 | A Microscale Platform for Augmentation of Cell Transduction (MPACT) to Enhance Ex Vivo Gene Transfer | 000 | 1 | NIH | 12/1/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $977,050 ) |
| | 2019 | 2019 | EXPRESSION THERAPEUTICS LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R43HL146045 | A Microscale Platform for Augmentation of Cell Transduction (MPACT) to Enhance Ex Vivo Gene Transfer | 000 | 1 | NIH | 4/18/2019 | $224,999 |
| | 2019 | 2019 | EXPRESSION THERAPEUTICS LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R44HL110448 | Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic | 000 | 3 | NIH | 8/11/2019 | $752,051 |
| | 2019 | 2017 | EXPRESSION THERAPEUTICS LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R43HL135969 | Preclinical Evaluation of Ancestral Coagulation Factor VIII | 000 | 1 | NIH | 12/11/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $747,641 ) |
| | 2018 | 2018 | EXPRESSION THERAPEUTICS LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R44HL110448 | Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic | 000 | 2 | NIH | 8/8/2018 | $747,641 |
| | 2018 | 2016 | EXPRESSION THERAPEUTICS LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R43HL132725 | Selection and preclinical validation of a lead candidate liver-directed AAV-FVIII expression cassette | 000 | 1 | NIH | 6/27/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $224,976 ) |
| | 2017 | 2017 | EXPRESSION THERAPEUTICS LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R43HL135969 | Preclinical Evaluation of Ancestral Coagulation Factor VIII | 000 | 1 | NIH | 1/24/2017 | $224,976 |
| | 2017 | 2015 | EXPRESSION THERAPEUTICS LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R44HL114241 | Bioengineered factor VIII gene therapy for hemophilia A | 000 | 3 | NIH | 6/2/2017 | $0 |
| | 2017 | 2015 | EXPRESSION THERAPEUTICS LLC | 1860 MONTREAL RD | TUCKER | GA | 30084-5709 | DEKALB | USA | R44HL117511 | Bioengineered Recombinant FVIII | 000 | 3 | NIH | 3/2/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $224,223 ) |
| | 2016 | 2016 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R43HL132725 | Selection and preclinical validation of a lead candidate liver-directed AAV-FVIII expression cassette | 000 | 1 | NIH | 8/3/2016 | $224,223 |
|
| Issue Date FY: 2015 ( Subtotal = $1,500,388 ) |
| | 2015 | 2015 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R44HL114241 | Bioengineered factor VIII gene therapy for hemophilia A | 000 | 3 | NIH | 5/4/2015 | $826,775 |
| | 2015 | 2015 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R44HL117511 | Bioengineered Recombinant FVIII | 000 | 3 | NIH | 1/9/2015 | $673,613 |
|
| Issue Date FY: 2014 ( Subtotal = $1,469,004 ) |
| | 2014 | 2014 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R44HL117511 | Bioengineered Recombinant FVIII | 001 | 2 | NIH | 3/14/2014 | $80,992 |
| | 2014 | 2014 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R44HL117511 | Bioengineered Recombinant FVIII | 000 | 2 | NIH | 1/31/2014 | $728,926 |
| | 2014 | 2014 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R44HL114241 | Bioengineered factor VIII gene therapy for hemophilia A | 000 | 2 | NIH | 4/23/2014 | $659,086 |
|
| Issue Date FY: 2013 ( Subtotal = $386,432 ) |
| | 2013 | 2013 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R43HL117511 | MANUFACTURING PROCESS DEVELOPMENT FOR BIOENGINEERED FVIII | 000 | 1 | NIH | 1/23/2013 | $386,432 |
|
| Issue Date FY: 2012 ( Subtotal = $674,776 ) |
| | 2012 | 2012 | EXPRESSION THERAPEUTICS | 1441 LOGAN CIRCLE | MARIETTA | GA | 30062 | COBB | USA | R43HL110448 | DEVELOPMENT OF A NOVEL PRODUCTION PLATFORM FOR COMPLEX RECOMBINANT BIOTHERAPEUTIC | 001 | 1 | NIH | 8/3/2012 | $296,320 |
| | 2012 | 2012 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R43HL114241 | BIOENGINEERED FACTOR VIII GENE THERAPY FOR HEMOPHILIA A | 000 | 1 | NIH | 6/14/2012 | $378,456 |
| | 2012 | 2012 | EXPRESSION THERAPEUTICS | 1441 LOGAN CIRCLE | MARIETTA | GA | 30062 | COBB | USA | R43HL110448 | DEVELOPMENT OF A NOVEL PRODUCTION PLATFORM FOR COMPLEX RECOMBINANT BIOTHERAPEUTIC | 001 | 1 | NIH | 8/3/2012 | -$296,320 |
| | 2012 | 2012 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R43HL110448 | DEVELOPMENT OF A NOVEL PRODUCTION PLATFORM FOR COMPLEX RECOMBINANT BIOTHERAPEUTIC | 000 | 1 | NIH | 8/1/2012 | $296,320 |
|
| Issue Date FY: 2011 ( Subtotal = $885,011 ) |
| | 2011 | 2011 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R42HL090112 | HIGH EXPRESSION RECOMBINANT FACTOR VIII | 000 | 3 | NIH | 6/30/2011 | $885,011 |
| | 2011 | 2010 | EXPRESSION THERAPEUTICS | 1441 LOGAN CIRCLE | MARIETTA | GA | 30062 | COBB | USA | R42HL083531 | EX VIVO GENE THERAPY FOR HEMOPHILIA A | 000 | 3 | NIH | 3/2/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $995,593 ) |
| | 2010 | 2010 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R42HL090112 | HIGH EXPRESSION RECOMBINANT FACTOR VIII | 000 | 2 | NIH | 6/16/2010 | $575,118 |
| | 2010 | 2010 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R42HL083531 | EX VIVO GENE THERAPY FOR HEMOPHILIA A | 000 | 3 | NIH | 1/28/2010 | $420,475 |
|
| Issue Date FY: 2009 ( Subtotal = $706,219 ) |
| | 2009 | 2009 | EXPRESSION THERAPEUTICS | 2205 Corp Plz Pkwy SE | Smyrna | GA | 30080-2970 | COBB | USA | R42HL083531 | EX VIVO GENE THERAPY FOR HEMOPHILIA A | 000 | 2 | NIH | 1/29/2009 | $706,219 |
|
| Issue Date FY: 2008 ( Subtotal = $100,000 ) |
| | 2008 | 2008 | EXPRESSION THERAPEUTICS | 1441 LOGAN CIRCLE | MARIETTA | GA | 30062 | COBB | USA | R41HL090112 | HIGH EXPRESSION RECOMBINANT FACTOR VIII | 000 | 1 | NIH | 4/7/2008 | $100,000 |
|
|
